From weight loss to loss of vision

As Ozempic, Wegovy & Mounjaro revolutionise diabetes and obesity treatments, scientists find these drugs increase the risk of serious eye conditions & vision loss

- 

Drugs such as Ozempic, Wegovy, and Mounjaro have changed the way clinicians manage diabetes and obesity around the world. Collectively known as GLP-1 agonists, these drugs mimic the hormone GLP-1. This limits both hunger and interest in food, helping users lose weight, and helps control blood sugar levels.

But two new studies that have been published show that people taking these drugs may have a small increased risk of serious eye conditions and vision loss.

Here's what you need to know if you're taking or considering these medications.

What damage can occur?

Non-arteritic anterior ischaemic optic neuropathy, or NAION, is a rare but devastating eye condition that occurs when blood flow to the optic nerve is suddenly reduced or blocked. It's also called an "eye stroke".

The exact cause of NAION remains unclear, and there are no current treatments available. People with diabetes are at increased risk of developing NAION.

Unlike other eye conditions that develop gradually, NAION causes a sudden, painless loss of vision. Patients typically notice the condition when they wake up and discover they've lost vision in one eye.

Vision tends to worsen over a couple of weeks and slowly stabilises. Recovery of vision is variable, but around 70 per cent of people do not experience improvement in their vision.

What has previous research shown?